- Comparison of carboplatin plus etoposide with amrubicin monotherapy for
extensive-disease small cell lung cancer in the elderly and patients with
poor performance status.
Igawa S, Shirasawa M, Ozawa T, Nishinarita N, Okuma Y, Ono T, Sugimoto A,
Kurahayashi S, Sugita K, Sone H, Fukui T, Mitsufuji H, Kubota M, Katagiri M,
Sasaki J, Naoki K.
Thorac Cancer. 2018 9:967-973.
- Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
Sone H, Igawa S, Kasajima M, Ishihara M, Hiyoshi Y, Hosotani S, Ohe S, Ito H, Kaizuka N, Manaka H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
Thorac Cancer. 2018 9:1279-1284.
- Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced
Non-Small-Cell Lung Cancer: A Prospective Observational Study.
Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H,
Kubota M, Hiyoshi Y, Ishihara M, Kasajima M, Sasaki J, Naoki K. Activity of
Nivolumab and Utility of Clin Lung Cancer. 2018 S1525-7304(18)30103-7.
- Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine
Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR
Mutations.
Nishinarita N, Igawa S, Kasajima M, Kusuhara S, Harada S, Okuma Y, Sugita K,
Ozawa T, Fukui T, Mitsufuji H, Yokoba M, Katagiri M, Kubota M, Sasaki J,
Naoki K.
Oncology. 2018;95:109-115.
- The role of prophylactic cranial irradiation for patients with small-cell
lung cancer.
Nakahara Y, Sasaki J, Fukui T, Otani S, Igawa S, Hayakawa K, Masuda N.
Jpn J Clin Oncol. 2018 48:26-30.
- Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
Igawa S, Otani S, Nakahara Y, Ryuge S, Hiyoshi Y, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sato Y, Sasaki J, Masuda N.
Investigational New Drugs, 2018 36: 45-52.
-
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S, Shirasawa M, Fukui T, Nishinarita N, Sone H, Ozawa T, Sugita K, Okuma Y, Kurahayashi S, Ono T, Sugimoto A, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
Oncology. 2018;94(4):207-214.
-
Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma.
Matsumoto T, Nagashio R, Ryuge S, Igawa S, Kobayashi M, Fukuda E, Goshima N, Ichinoe M, Jiang SX, Satoh Y, Masuda N, Murakumo Y, Saegusa M, Sato Y.
Pathol Int. 2018;68(4):232-240.
-
Prognostic significance of S100A16 sub-cellular localization in lung adenocarcinoma.
Kobayashi M, Nagashio R, Saito K, Aguilar-Bonavides C, Ryuge S, Katono K, Igawa S, Tsuchiya B, Jiang SX, Ichinoe M, Murakumo Y, Saegusa M, Satoh Y, Sato Y.
Hum Pathol. 2018 Jan 7. [Epub ahead of print]
- Pharmacological and structural characterizations of naquotinib, a novel
third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.
Mol Cancer Ther. 2018 Feb 21.[Epub ahead of print] Hirano T, Yasuda H,
Hamamoto J, Nukaga S, Masuzawa K, Kawada I, Naoki K, Niimi T, Mimasu S,
Sakagami H, Soejima K, Betsuyaku T.
- Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous
non-small-cell lung cancer combined with exploratory analysis of circulating
endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K,
Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M,
Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H. BMC Cancer. 2018;18(1):241.
- Prognostic significance of G6PD expression and localization in lung adenocarcinoma.
Nagashio R, Oikawa S, Yanagita K, Hagiuda D, Kuchitsu Y, Igawa S, Naoki K,Satoh Y, Ichinoe M, Murakumo Y, Saegusa M, Sato Y.
Biochim Biophys Acta. 2018 18:30072-4.
- Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer.
Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T.
Onco Targets Ther. 2018 :11:3335-3343.
- Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients.
Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, Hamamoto Y.
Asia Pac J Oncol Nurs. 2018;5:172-177.
- Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease.
Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K.
Cancer Manag Res. 2018;10:7013-7019
- Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer.
Yanagita K, Nagashio R, Jiang SX, Kuchitsu Y, Hachimura K, Ichinoe M, Igawa S, Fukuda E, Goshima N, Satoh Y, Murakumo Y, Saegusa M, Sato Y.
Am J Pathol. 2018 ;188:1328-1333.
- Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer.
Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Ishihara M, Kasajima M, Nakahara Y, Otani S, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.
Cancer Manag Res. 2018;21:6039-6047.